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Summary
Dengue disease is a mosquito-borne infection caused by Dengue virus. Infec-
tion may be asymptomatic or variably manifest as mild Dengue fever (DF) to
the most severe form, Dengue haemorrhagic fever (DHF). Mechanisms that
influence disease severity are not understood. Complement, an integral com-
ponent of the immune system, is activated during Dengue infection and the
degree of activation increases with disease severity. Activation of the comple-
ment alternative pathway is influenced by polymorphisms within activation
(factor B rs12614/rs641153, C3 rs2230199) and regulatory [complement
factor H (CFH) rs800292] proteins, collectively termed a complotype. Here,
we tested the hypothesis that the complotype influences disease severity
during secondary Dengue infection. In addition to the complotype, we also
assessed two other disease-associated CFH polymorphisms (rs1061170,
rs3753394) and a structural polymorphism within the CFH protein family.
We did not detect any significant association between the examined
polymorphisms and Dengue infection severity in the Thai population.
However, the minor allele frequencies of the factor B and C3 polymorphisms
were less than 10%, so our study was not sufficiently powered to detect an
association at these loci. We were also unable to detect a direct interaction
between CFH and Dengue NS1 using both recombinant NS1 and DV2-
infected culture supernatants. We conclude that the complotype does not
influence secondary Dengue infection severity in the Thai population.
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Introduction
Dengue disease, a mosquito-borne infection, is a public
health concern in many subtropical and tropical countries.
The causative agent is Dengue virus (DV), a positive-sense
single-stranded RNA virus and a member of the
Flaviviridae family. This virus can be classified into four
serotypes (DV 1–4) whose genomes are closely related but
distinct. The genome expresses three structural proteins
(Capsid, PrM and Envelop protein), and seven non-
structural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b
and NS5). DV infection may be asymptomatic or manifest
as undifferentiated fever, Dengue fever (DF) or Dengue
haemorrhagic fever (DHF) with plasma leakage. DHF can
be classified on severity into four subtypes (DHF 1–4). The
most severe disease, which has been termed Dengue shock
syndrome (DSS), comprises a syndrome of plasma leakage
with shock and severe bleeding [1]. Both the host immune
response and the DV strain contribute to the development
of DHF [2–4]. Non-neutralizing antibodies enhance infec-
tivity in an Fc-dependent manner [5]. A number of host
susceptibility genes have been identified and include
genes encoding: Fc gamma receptor II (FcγRIIA), human
leucocyte antigens (HLA-A1, and HLA-A2), the vitamin D
receptor, tumour necrosis factor (TNF)-α and dendritic
cell-specific intercellular adhesion molecule-3-grabbing
non-integrin (DC-SIGN) [6–8].
The complement system is an integral component of host
defence and appears to influence the host response to
flavivirus infection in murine models. Mice lacking comple-
ment components [C3, C1q, C4 or factor B (FB)] were
more susceptible to West Nile virus (WNV) infection [9].
Activation of complement increased antibody-mediated
neutralization of flavivirus, as C1q reduced the antibody-
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dependent enhancement of both WNV and DV infection
[10]. Complement activation occurs during the course of
DV infection. An increase in C3 activation, together with
reduced levels of C4 and FB, has been shown in DHF [11].
C3 levels were reduced while the levels of C3a and C5a
(anaphylatoxins) were increased in DHF compared to DF
[12]. C5b-9 complexes, along with high levels of DV NS1
protein, correlated with DV infection severity [13].
The molecular mechanisms through which complement
could influence flavivirus infection are incompletely under-
stood. DV NS1 can bind complement C4, a classical and
lectin pathway activation protein and trigger C4 degrada-
tion [14]. WNV NS1 binds the complement regulatory
protein, complement factor H (CFH), an interaction
that prevented the lysis of WNV-infected cells [15]. In con-
trast, Japanese encephalitis virus (JEV) NS1 did not bind
CFH and did not modulate the host innate immune
response [16].
Recently, it has been shown that polymorphisms (collec-
tively termed ‘complotype’) in complement proteins C3, FB
and CFH can be associated with an up to sixfold variation
in complement haemolytic activity in vitro [17]. C3 and FB
are activation proteins of the complement alternative
pathway, while CFH is the major regulator of this pathway.
Therefore, the description of the complotype demonstrated
that alternative pathway activation is influenced by genetic
factors. These polymorphisms have been associated with
susceptibility to age-related macular degeneration (AMD
[18–20]), suggesting that the degree of haemolytic activa-
tion driven by these polymorphisms in vitro is biologically
relevant. Individuals with the ‘high activation’ complotype
have increased susceptibility to AMD [FB-32 R/R: rs12614
(C) and rs641153 (G); CFH-62 V/V: rs800292 (G); and
C3-102 F/F: rs2230199 (G)], whereas risk is reduced in
those with the ‘low activation’ complotypes [FB-32 Q/Q
rs12614 (C) and rs641153 (A); CFH-62 I/I: rs800292 (A);
and C3-102 S/S: rs2230199 (C)]. Consistent with these data
was the finding that serum complement activation appears
to be enhanced in AMD [21].
In addition, genetic variation across the CFH–CFHR
locus (the region encoding CFH and CFH-related proteins)
is linked to AMD susceptibility. This variation includes a
polymorphism within CFH (CFH-402 Y/H, rs1061170,
[22]) and a copy number polymorphism that results in
deletion of the CFHR1 and CFHR3 genes (ΔCFHR3-1,
[23]). Recently, CFH promoter (–332 C/T, rs3753394) and
CFH (V62I, rs800292) polymorphisms have been associated
with Dengue disease [24]. The functional consequences of
these polymorphisms are not understood.
Although studies have implicated a role for complement
in DV infection severity, only one study to date has explored
the relationship between complement genetic variation and
DV infection [24]. In this study we specifically analysed the
relationship between DV infection severity and the
complotype (CFH rs800292, FB rs12614/rs641153 and C3
rs2230199), as this variation has been associated with differ-
ences in complement activation. We also included the
AMD-associated CFH rs1061170 variant, the CFH pro-
moter rs3753394 variant and the ΔCFHR3-1 deletion poly-
morphism. We did not find any strong correlation between
DV infection severity and these specific polymorphisms.
Our data demonstrate that variation in these polymor-
phisms is not a major host factor for determining the phe-
notypic response to this infection.
Materials and methods
Patients and controls
Genomic DNA samples were extracted from patients
attending either Khon-Kean or Song-Khla Hospitals, Thai-
land. Viral diagnosis was established using reverse
transcription–polymerase chain reaction (RT–PCR) and
severity classified using World Health Organization (WHO)
guidelines: DF and DHF grades 1–4. Dengue immuno-
globulin (Ig)G/IgM capture enzyme-linked immunosorbent
assay (ELISA) was used to classify primary and secondary
infection. An IgM : IgG ratio equal to or greater than 1·8
was used to define primary infection [25]. Patients with
other febrile illnesses (OFI) (n = 63) were those presenting
with fever and having undetectable Dengue viral genome
and levels of anti-Dengue antibodies lower than the cut-off
value for an acute Dengue infection. Healthy volunteers
were recruited from Siriraj Hospital, Thailand. Written
informed consent was obtained and sample collection
approved by the Institutional review board.
Genotyping
Genomic DNA was amplified by PCR using high-fidelity
polymerase (Certamp; Biotools, Madrid, Spain) and
primers listed in Table S1. Following purification
(ChargeSwitch PCR clean-up kit; Invitrogen, Carlsbad, CA,
USA) amplicons were sequenced and single nucleotide
polymorphism (SNP) genotype-recorded. The CFH
rs800292 variant was determined using the Taqman SNP
genotyping assay (no. 4351379; Applied Bioscience, Island,
NY, USA). ΔCFHR3-1 copy number was detected using a
combination of (i) Taqman copy number assay probes
(Applied Bioscience), (ii) genotyping of rs6677604 (a SNP
within intron 12 of the CFH gene that has been shown to
tag the ΔCFHR3-1 deletion) [26] and (iii) multiplex
ligation-dependent probe amplification assay (MLPA; MRC
Holland, the Netherlands). MLPA was performed according
to the manufacturer’s instructions. PCR products were
mixed with GeneScan 500 ROX Size Standard (Applied
Bioscience) in Hi-Di formamide (Applied Bioscience) and
separated using capillary electrophoresis (3730xl DNA Ana-
lyser; Applied Biosystems, Grand Island, NY, USA).
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Dengue virus infection in vitro
C6/36 cell lines were cultured in 10% fetal bovine serum
(FBS), 10% tryptose-phosphate-broth (TPB) Leibovitz L-15
with streptomycin and penicillin at 28°C. Vero cell lines
were maintained with modified Eagle’s medium (MEM)
supplemented with 10% FBS at 37°C in a CO2 incubator.
Dengue virus serotype 2 strain 16681 (DV2) was propa-
gated in C6/36 cells. Infected cells were incubated further at
28°C until a cytopathic effect (CPE) could be seen. Mock
was used as a negative control. To titrate the virus in the
supernatant, Vero cells were plated on each well in a 96-well
plate and incubated for 2 days in a CO2 incubator. On the
day of infection, the supernatant were serially diluted
10-fold with 3% MEM and added to the cells for 2 h at
37°C. The infected cells were then overlaid with 1·5%
carboxymethylcellulose and incubated further for 2 days.
Infected foci were observed by immunoperoxidase staining.
Briefly, the infected cells were washed with PBS, fixed and
permeabilized with 3·7% formaldehyde and 2% Triton-X
100, respectively. Monoclonal antibody against Dengue E
protein (4G2) and rabbit anti-mouse-horseradish
peroxidase (HRP) diluted in 1/1000 (Dako, Glostrup,
Denmark) were added sequentially before adding 3,3′-
diaminobenzidine tetrahydrochloride (DAB) (Sigma-
Aldrich, St Louis, MO, USA). The number of foci were
counted and reported as foci-forming units per ml.
CFH and NS1 interaction assays
To determine if CFH interacted with NS1 we utilized
ELISA, far Western and immunopreciptiation techniques.
For ELISA, 5 μg/ml human CFH (Quidel, San Diego, CA,
USA) in carbonate buffer was coated on a 96-well MaxiSorp
plate (Nunc, Roskilde, Denmark) at 4°C overnight. Either
mock or DV2 supernatant was then added to wells and
incubated at 37°C for 1 h. NS1 was detected by adding
5 μg/ml monoclonal mouse anti-NS1 antibody (1F11) fol-
lowed by alkaline phosphatase-conjugated goat anti-mouse
antibody (Sigma-Aldrich) and substrate (0·001 mg/ml
p-nitrophenylphosphate; Bio-Rad, Hercules, CA, USA). The
reciprocal approach comprised coating of plates with
10 μg/ml 1F11 followed by sequential addition of superna-
tants and 5 μg/ml CFH. CFH was detected using goat anti-
human CFH (Quidel) followed by HRP-conjugated mouse
anti-goat antibody (Sigma-Aldrich) and substrate (3,3′,5,5′-
tetramethylbenzidine).
For far Western blotting, mock and DV2 supernatant was
separated using sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE). Following membrane
transfer, membranes were incubated with 5 μg/ml CFH.
Following washing, either goat anti-human factor CFH
(Quidel) or 1F11 was used to detect CFH and NS1, respec-
tively. CFH (0·5 μg) was also applied to non-reducing gels,
and following transfer, membrane-incubated with either
mock or DV2 supernatant. Following washing, either goat
anti-human factor CFH (Quidel) or 1F11 was used to detect
CFH and NS1, respectively. Recombinant NS1 (rNS1;
Abcam, Cambridge, UK) was also tested for interaction
with CFH.
For co-immunoprecipitation, mock or DV2 supernatant
was incubated with 5 μg/ml CFH for 3 h at 4°C followed by
1F11 for 1 h. Protein A (Roche, San Francisco, CA, USA)
was then added and the mixture was rotated overnight.
After centrifuging, beads were washed three times using
0·1% PBS-T, bound protein eluted using non-reducing
loading buffer and eluate analysed by SDS-PAGE. NS1 and
CFH were detected using 1F11 and goat anti-human CFH
antibody, respectively (Quidel).
Statistical analyses
The analyses were performed on SPSS version 19·0 (SPSS,
Inc., Chicago, IL, USA). Hardy–Weinberg equilibrium and
association tests were carried out by using the χ2 test. Odds
ratio (OR) was the odds of the genotype comparing either
DHF to DF or DHF with shock to DHF without shock.
Logistic regression model was used to adjust OR with sex
and age. Bonferroni’s correction was performed by dividing
α-level with the total number of polymorphisms compared
(n = 6) to obtain an adjusted P-value of 0·05/6 = 0·008.
Results
Study population
The study population demographics are depicted in Table 1.
The age of patients with either Dengue infection or non-
Dengue febrile infection was 2–15 years. The range for
healthy controls was higher, at 19–47 years. The number of
males and females within each of the three groups was com-
parable with the exception of the DHF4 subgroup, which
was comprised of two females. We included only patients
with secondary infection.
Complement gene polymorphisms did not differ in
frequency between patients with severe and non-severe
Dengue infection in the Thai population
The individual SNP frequencies in FB (rs12614, rs641153),
C3 (rs2230199) and CFH (rs3753394, rs1061170 and
rs800292) did not differ between patients with Dengue
infection and either healthy controls or individuals with
non-Dengue febrile illness (Table S2). We next examined
whether the SNP frequencies differed among Dengue infec-
tion subgroups, defined as those with DF (n = 121) and
those with DHF (n = 187). We also compared genotypes
between DHF patients with (n = 43, defined as DHF3 and
DHF4) and without shock (n = 144 defined as DHF1 and
DHF2, Table 2). No differences were noted for any of the
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tested polymorphisms. Notably, the minor allele frequency
of functional C3 rs2230199 polymorphism was low (2%), as
were the minor allele frequencies of the adjacent rs12614
and rs641153 FB polymorphisms (<10%). In contrast, the
CFH rs800292 polymorphism had a minor allele frequency
of 42% in this population, but nevertheless its frequency
did not differ between Dengue infection subgroups. Due to
the rarity of variation at C3 rs2230199, FB rs12614 and FB
rs641153FB we did not detect any individual in our Dengue
infection cohort with either the most [C3F/F, FB-32R/R
(C/G at the adjacent rs12614/rs641153) and CFH 62V/V] or
least [C3S/S, FB-32Q/Q (C/A at the adjacent rs12614/
rs641153) and CFH 62I/I] active complotype described in
vitro (Table 3) [17]. One high (defined as FB-32R/R and
CFH 62V/V) and one low (defined as CFH 62I/I and C3S/S)
activation complotype were present in our Dengue infec-
tion cohort, but neither was associated with infection sever-
ity (Table 3).
The CFHR3-1 deletion polymorphism is not associated
with Dengue infection severity
The ΔCFHR3-1 deletion allele frequency in our controls
(healthy and non-Dengue febrile illness) and Dengue infec-
tion was 6·79 and 6·94%, respectively, and did not differ
significantly between these two groups or between
subgroupings of Dengue infection (Table 4). In this analy-
sis, we noted one individual with three copies of CFHR3-1,
suggesting duplication of these genes on one allele. In addi-
tion, nine individuals had heterozygous deletion of the
CFHR1 gene in the presence of two copies of the CFHR3
genes. This is most likely to indicate the presence an allele
containing deletion of both the CFHR1 and CFHR4 genes
(ΔCFHR4-1), a variant reported in healthy controls, but
at a lower frequency than that of the ΔCFHR3-1 deletion
allele [27].
Dengue NS1 protein did not bind to the complement
factor H protein
NS1 protein of WNV virus has an immune evasion activity
by binding to CFH protein, resulting in decreased comple-
ment recognition of infected cells [15]. We next determined
if Dengue NS1 interacts with CFH using either recombi-
nant NS1 or NS1 from DV2-infected cell supernatants
(Fig. 1). Using a combination of ELISA, far Western
blotting and immunoprecipitation assays we could not
detect any evidence of an interaction between CFH and
Dengue NS1 (Fig. 1). As a positive control for the far
Western blotting, we utilized the known interaction
between CFH and the meningococcal factor H-binding
protein (Fig. S1).
Discussion
In this study we assessed the relationship of selected com-
plement gene polymorphisms and Dengue infection sever-
ity. We included variation within four nucleotides, two
adjacent in FB and one in each of C3 and CFH, that have
been shown to determine a sixfold variation in comple-
ment haemolytic activity in vitro [17]. Our data showed
that the minor allele frequency in the C3 and FB
polymorphisms was very low, and consequently any popu-
lation effect of variation at this locus would be minimal
and difficult to detect without large numbers. However,
although the minor allele frequency at the CFH rs800292
polymorphism was 42% (Table 2), we did not detect any
significant variation in the distribution of genotypes
among the subgroups of Dengue infection. A recent study
of 121 Brazilian patients with DENV-3 (genotype III Sri
Lankan–Indian strain) assessed the relationship between
four CFH polymorphisms (rs3753394, rs800292,
rs3753396, rs1065489) and infection severity [24]. The
minor alleles at rs3753394 and rs800292 were associated
with reduced infection severity. Our analysis included these
loci, but did not replicate the association. Hence, if the
association is robust in the Brazilian population, it does not
apply in the Thai population.
Retrospective studies of Dengue infection have shown a
correlation between the disease severity and the comple-
ment activation [11,12]. Plasma CFH was lower in patients
with DHF during the acute phase of the illness, returning to
normal during convalescence. In contrast CFH levels did
not alter during DF infection [12]. However, in this study
Table 1. Study population demographics.
Group n
Sex Age
Male Female Median Range
Healthy 22 9 13 21 19–47
Other febrile illnesses (OFI) 63 28 35 8 2–15
DF 121 61 60 10 3–15
DHF1 68 35 33 9·5 2–15
DHF2 76 47 29 11 5–15
DHF3 41 19 22 10 4–15
DHF4 2 0 2 7·5 5–10
Healthy and other febrile illness (OFI) subgroups were utilized as non-Dengue controls. DF: Dengue fever; DHF1–4: Dengue haemorrhagic
fever 1–4.
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we did not find a significant correlation with severity and
the examined CFH polymorphisms.
The absence of the genes encoding the CFH-related pro-
teins, CFHR1 and CFHR3, is a frequent polymorphism
(ΔCFHR3-1), which is thought to have developed through
non-allelic homologous recombination within the CFHR
locus [22,23]. This allele confers protection against AMD
and IgA nephropathy [23,28]. The frequency of the
ΔCFHR3-1 allele in our Dengue population was approxi-
mately 7% (Table 4). The reported allele frequencies in
other populations include 4·7% in European Caucasians,
16% in African populations and 2% in Asians [22]. In our
analysis there was no evidence that this allele conferred pro-
tection against Dengue infection or its severity. During copy
number analysis across the CFHR locus we noted uncom-
mon but previously reported variation, including one indi-
vidual with three copies of the CFHR3 and CFHR1 genes,
most probably a result of duplication of theses genes on one
allele [29,30]. We also detected nine individuals with dele-
tion of the CFHR1 gene but normal copies of the CFHR3
genes. One explanation for these findings is the presence of
a less common allele in which there is deletion of the
CFHR4 and CFHR1 genes (ΔCFHR4-1). Alternatively, this
could represent deletion of the CFHR1 genes in isolation
[27,31]. Our copy number analysis did not include probes
for CFHR4 gene, so this remains to be shown.
It is important to note that in our study we excluded
individuals with primary infection, because in many cases
infection is asymptomatic. Secondly, our sample size for
severe disease (DHF3 and DHF4) was relatively small, and it
remains possible that we could lack the power to detect
small effects. Thirdly, the low frequency of the minor allele
of the studied C3 and FB polymorphisms means that we
cannot conclude what effects variation could have on infec-
tion severity in non-Thai populations, where there is greater
variation at these loci.
Levels of Dengue soluble NS1 protein correlates with
disease severity [32] and Dengue soluble NS1 protein can
directly activate the complement cascade, a phenomenon
that is enhanced by the presence of anti-Dengue antibodies
[13]. Dengue NS1 has been shown to interact with
Clusterin, a complement regulatory protein [33]. Recently,
some studies have shown that WNV NS1, but not JEV,
could bind to CFH, and thereby reduce complement activa-
tion on the virus in vitro [15,16]. We were unable to detect a
direct interaction between CFH and Dengue NS1 protein,
so we currently have no evidence to suggest that NS1 inter-
feres with CFH-mediated regulation of complement during
infection, at least in a direct manner.
In summary, our data demonstrate that the severity of
Dengue infection is not influenced strongly by the CFH
rs3753394 promoter polymorphism, the AMD-associated
CFH rs1061170 polymorphism, the AMD-protective
ΔCFHR3-1 allele and the complotype-associated CFH
rs800292 polymorphism in Thai population. We also showTa
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that the complotype-associated C3 rs2230199 and FB
rs12614/rs641153 polymorphisms had very low minor allele
frequencies in this population. Finally, we could not dem-
onstrate a direct interaction between CFH and Dengue
NS1. We conclude that these genetic factors do not influ-
ence the severity of Dengue infection in the Thai popula-
tion and that Dengue NS1 does not influence complement
activation during infection by a direct interaction with
CFH.
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Table 4. Copy number variation in CFHR3 and CFHR1 genes and Dengue virus infection severity.
Sample: n
CFHR3-1
P-value
CHFR1-CFHR3 deletion
CHFR3-1 CFHR1
100% 50% 0% 150% 50%
(2 copies) (1 copy) (0 copy) ΔCFHR3-1 allele frequency (%) (3 copies) (1 copy)
Controls 82 70 11 0 6·79 0 1
Dengue 297 251 34 3 1·00† 6·94 1 8
DF 113 95 14 0 6·42 0 4
DHF 184 156 20 3 0·74‡ 7·26 1 4
No shock 142 118 16 3 8·03 1 4
Shock 42 38 4 0 0·47§ 4·76 0 0
Controls include healthy controls and other febrile illness, 150%, three copies of CFHR3-1; 100%, two copies of CHFR3-1; 50%, one copy
of CHFR1-3; 0%, no copies of the CFHR3-1 genes ΔCFHR3-1 allele frequency is the percentage of ΔCFHR3-1 alleles divided by total CFHR3-1
alleles. †Dengue versus controls; ‡DF versus DHF; §no shock versus shock.
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Fig. 1. Assays exploring possible interaction
between complement factor H (CFH) and
Dengue non-structural protein 1 (NS1). (a) and
(b) enzyme-linked immunosorbemt assays
(ELISA) to detect interaction between CFH and
NS1. (a) Supernatants were added to plates
coated with human CFH (5 μg/ml) and binding
detected with anti-NS1 antibody. (b) Anti-NS1
antibody was coated on the plate and NS1
captured from Dengue virus (DV)2-infected cell
supernatant. Purified CFH was then added and
binding detected using an anti-CFH antibody.
The experiments were performed three times
independently. (c,d,e) Far Western blotting
assays to detect interaction between CFH
and NS1. CFH (c), supernatant (d) and
recombinant NS1 (e) were immobilized using
gel electrophoresis. Following addition of
supernatant (c), recombinant NS1 (c) and CFH
(d,e) interaction was tested by addition of the
appropriate antibodies. (f)
Immunoprecipitation assay to detect interaction
between CFH and NS1. Immunoprecipitation
using anti-NS1 antibody (lanes 2 and 3)
demonstrated NS1 in the absence of CFH in
DV2-infected cell supernatants only. In lane 1
purified CFH was loaded on to the gel as a
positive control for CFH detection by the
anti-CFH antibody.
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Fig. S1. Far Western blot between Neisseria complement
factor H binding protein (fHbp) and complement factor H
(CFH). fHbp protein (a gift from Professor Chris Tang,
University of Oxford, UK) was loaded into the gel, trans-
ferred to a membrane which was then incubated with
human CFH (lane 1, 5 μg/ml; Quidel, San Diego, CA, USA)
or buffer (lanes 2 and 3). The interaction between gel-
immobilized fhbp and the added CFH was detected using
an anti-human CFH antibody (lane 1, antibody obtained
from Quidel). Gel-immobilized fHbp was visualized using
an anti-fHbp (lane 2, antibody a gift from Professor Chris
Tang, University of Oxford, UK). The anti-human CFH
antibody did not recognize gel-immobilized fhbp in the
absence of CFH (lane 3).
Table S1. Primer sequences used in custom genotyping
assays.
Table S2. Relationship of complement gene polymorphisms
between Dengue infection and controls.
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